Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90(162 visite) Nardelli A, Castaldi E, Ortosecco G, Speranza A, Storto G, Pace L, Salvatore M
Parole chiave: 90y, Dota-Peptides, Radiolabelling, Radionuclide Therapy, 90< Sup>y, Critical Factors, Effective Therapy, High Activity, Impact Reaction, Peptide Receptor, Radiochemical Yield, Reaction Conditions, Reaction Temperature, Specific Activity, Statistically Significant Difference, Temperature Constant, Water Baths, Yttrium-90, Association Reactions, Group Technology, High Performance Liquid Chromatography, Quality Control, Radioisotopes, Thin Layer Chromatography, Yttrium Alloys, Reaction Kinetics, 10 Tetraazacyclododecane 1, 10 Tetraacetic Acid, Article, Chemical Reaction Kinetics, Controlled Study, Isotope Labeling, Priority Journal, Radioactivity, Radiochemistry, Heterocyclic Compounds, 1-Ring, Humans, Octreotide, Organometallic Compounds, Radiopharmaceuticals, Yttrium Radioisotopes, 1-Ring Chemistry
, Isotope Labeling Methods
, Octreotide Analogs, Derivatives Chemistry
, Organometallic Compounds Chemical Synthesis
, Radiopharmaceuticals Chemical Synthesis
, Yttrium Radioisotopes Chemistry,
Affiliazioni:
*** IBB - CNR *** Istituto di Biostrutture e Bioimmagini, Consiglio Nazionale delle Ricerche (CNR), Naples, Italy. a.nardelli@libero.it IRCCS-CROB, Rionero in Vulture, Italy Dipartimento di Scienze Biomorfologiche e Funzionali, Università Federico II, Via Pansini 5, 80131 Naples, Italy
Riferimenti:
Breeman, W.A., de Jong, M., Kwekkeboom, D.J., Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives (2001) Eur. J. Nucl. Med., 28, p. 142
Bunemann, M., Hosey, M.M., G-protein coupled receptor kinases as modulators of G-protein signalling (1999) J. Physiol., 517, p. 5
De Jong, M., Valkema, R., Jamar, F., Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings (2002) Semin Nucl. Med., 32, p. 133
Esser, J.P., Krenning, E.P., Teunissen, J.J., Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT? (2006) Eur. J. Nucl. Med. Mol. Imaging, 33, p. 1346
Forrer, F., Uusijärvi, H., Waldherr, C., A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours (2004) Eur. J. Nucl. Med. Mol. Imaging, 31, p. 1257
Kwekkeboom, D., Krenning, E.P., de Jong, M., Peptide receptor imaging and therapy (2000) J. Nucl. Med., 41, p. 1704
Krenning, E.P., Valkema, R., Kooij, P.P., The role of radioactive somatostatin and its analogues in the control of tumor growth (2000) Recent Results Cancer Res., 153, p. 1
Kwekkeboom, D.J., Bakker, W.H., Kooij, P.P., [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients (2001) Eur. J. Nucl. Med., 28, p. 1319
Kukis, D.L., DeNardo, S.J., DeNardo, G.L., Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates (1998) J. Nucl. Med., 39, p. 2105
Liu, S., Cheung, E., Ziegler, M.C., (90)Y and (177)Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy (2001) Bioconjugate Chem., 12, p. 559
Oberg, K., Kvols, L., Caplin, M., Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system (2004) Ann. Oncol., 15, p. 966
Plöckinger, U., Rindi, G., Arnold, R., European Neuroendocrine Tumour Society.Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS) (2004) Neuroendocrinology, 80, p. 394
Wild, D., Schmitt, J.S., Gini, M., DOTANOC, a high-affinity ligand of somatostatin receptors subtypes 2, 3 and 5 for labelling with various radiometals (2003) Eur. J. Nucl. Med., 30, p. 1338
Breeman, W. A., de Jong, M., Kwekkeboom, D. J., Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives (2001) Eur. J. Nucl. Med., 28, p. 142
Esser, J. P., Krenning, E. P., Teunissen, J. J., Comparison of [(177) Lu-DOTA (0), Tyr (3)] octreotate and [(177) Lu-DOTA (0), Tyr (3)] octreotide: which peptide is preferable for PRRT? (2006) Eur. J. Nucl. Med. Mol. Imaging, 33, p. 1346
Forrer, F., Uusij rvi, H., Waldherr, C., A comparison of (111) In-DOTATOC and (111) In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours (2004) Eur. J. Nucl. Med. Mol. Imaging, 31, p. 1257
Krenning, E. P., Valkema, R., Kooij, P. P., The role of radioactive somatostatin and its analogues in the control of tumor growth (2000) Recent Results Cancer Res., 153, p. 1
Kwekkeboom, D. J., Bakker, W. H., Kooij, P. P., [177Lu-DOTAOTyr3] octreotate: comparison with [111In-DTPAo] octreotide in patients (2001) Eur. J. Nucl. Med., 28, p. 1319
Kukis, D. L., DeNardo, S. J., DeNardo, G. L., Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates (1998) J. Nucl. Med., 39, p. 2105
Pl ckinger, U., Rindi, G., Arnold, R., European Neuroendocrine Tumour Society. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS) (2004) Neuroendocrinology, 80, p. 394
Kim YH, Shin SW, Pellicano R, Fagoonee S, Choi IJ, Kim YI, Park B, Choi JM, Kim SG, Choi J, Park JY, Oh S, Yang HJ, Lim JH, Im JP, Kim JS, Jung HC, Ponzetto A, Figura N, Malfertheiner P, Choi IJ, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, Park B, Nam BH, Bae SE, Choi KD, Choe J, Kim SO, Na HK, Choi JY, Ahn JY, Jung KW, Lee J, Kim DH, Chang HS, Song HJ, Lee GH, Jung HY, Seta T, Takahashi Y, Noguchi Y, Shikata S, Sakai T, Sakai K, Yamashita Y, Nakayama T, Leja M, Park JY, Murillo R, Liepniece-karele I, Isajevs S, Kikuste I, Rudzite D, Krike P, Parshutin S, Polaka I, Kirsners A, Santare D, Folkmanis V, Daugule I, Plummer M, Herrero R, Tsukamoto T, Nakagawa M, Kiriyama Y, Toyoda T, Cao X, Corral JE, Mera R, Dye CW, Morgan DR, Lee YC, Lin JT, Garcia Martin R, Matia Cubillo A, Lee SH, Park JM, Han YM, Ko WJ, Hahm KB, Leontiadis GI, Ford AC, Ichinose M, Sugano K, Jeong M, Park JM, Han YM, Park KY, Lee DH, Yoo JH, Cho JY, Hahm KB, Bang CS, Baik GH, Shin IS, Kim JB, Suk KT, Yoon JH, Kim YS, Kim DJ * Helicobacter pylori Eradication for Prevention of Metachronous Recurrence after Endoscopic Resection of Early Gastric Cancer(20 visite) NEW ENGL J MED (ISSN: 0028-4793), 2015 Jun; 30642104201566393291: 749-756. Impact Factor:59.558 DettagliEsporta in BibTeXEsporta in EndNote
Aloj L, Aurilio M, Rinaldi V, D'Ambrosio L, Tesauro D, Peitl PK, Maina T, Mansi R, Von Guggenberg E, Joosten L, Sosabowski JK, Breeman WA, De Blois E, Koelewijn S, Melis M, Waser B, Beetschen K, Reubi JC, De Jong M * The EEE project(111 visite) Proc Int Cosm Ray Conf Icrc Universidad Nacional Autonoma De Mexico, 2007; 5(HEPART2): 977-980. Impact Factor:0 DettagliEsporta in BibTeXEsporta in EndNote
680 Records (647 escludendo Abstract e Conferenze). Impact factor totale: 2514.63 (2436.247 escludendo Abstract e Conferenze). Impact factor a 5 anni totale: 2624.155 (2538.834 escludendo Abstract e Conferenze).
ibb.cnr.it
